The BioHub: The Top Voices in Biotech
The BioHub: The Top Voices in Biotech
Podcast Description
Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape.
Subscribe now and be part of the conversation that's shaping the future of biotechnology.
Get ready for an immersive experience into the world of biotech with The BioHub.
Podcast Insights
Content Themes
The podcast focuses on critical themes in biotechnology including innovative therapies, leadership challenges, market trends, and the intersection of science and business. Recent episodes cover topics such as the development of immune modulators for autoimmune diseases, innovative approaches to cell and gene therapy, and the latest advancements in cytokine therapies. For instance, Judy Chou discusses the future of AltruBio after a successful funding round, while Aoife Brennan shares insights on Climb Bio's novel strategies in cellular therapies.
Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape.
Subscribe now and be part of the conversation that’s shaping the future of biotechnology.
Get ready for an immersive experience into the world of biotech with The BioHub.
I’m here with Mike Exton, the CEO of LexiconPharmaceuticals.
Mike joined Lexicon in 2024 after two decades of leadershipacross Novartis and Eli Lilly, where he helped launch some of the biggest cardiovascular drugs in the world — including Entresto.
Now he’s leading Lexicon through a bold new chapter, with agenomics-driven pipeline focused on cardiometabolism and neuroscience, and a strategy built around delivering best-in-class or first-in-class medicines in areas of real unmet need.
Mike, great to have you here
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.